Thorsten Fuereder

6PUBLICATIONS
24CO-AUTHORS
Solid tumoursPredictive and prognostic markersNutrigenomics and personalised nutritionCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 10, 2024
SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy.

Alexander Michael Grandits, Barbara Andrea Reinoehl, Renate Wagner

|Dec 08, 2023
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.

Petar Popov, Ariane Steindl, Ladislaia Wolff

|Feb 25, 2023
The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.

Markus Haas, Alexander Lein, Thorsten Fuereder

|Feb 15, 2022
EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells.

Alexander Michael Grandits, Sophie Bromberger, Gerwin Heller

|Nov 27, 2021
Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients.

Thomas Bartl, Arina Onoprienko, Gerda Hofstetter

|Feb 08, 2018
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.

Hannah Fuchs, Johannes Pammer, Christoph Minichsdorfer

Pageof 1

Frequent Collaborators

2 joint publications

Alexander Michael Grandits

2 joint publications

Rotraud Wieser

1 joint publications

Thomas Bartl

1 joint publications

Leonhard Müllauer